SI-BONE Q1 revenue $32.7M (+46% YoY), raises FY2023 guidance to $128-131M

SI-BONE, Inc.

2023-Q1 EPS reported -$0.32 revenue$32,708,000

Record worldwide revenue $32.7M (+46% YoY); US revenue $30.5M (+50% YoY).
Net loss improved to $11.1M ($0.32/diluted share) from $17.4M ($0.52) a year ago.
Gross margin 82% (down from 87%) due to product mix, new implants, and higher freight/depreciation.
FY2023 revenue guidance raised to $128-131M, implying 20-23% annual growth.
Over 950 active US surgeons (+40% YoY); cash $86M, borrowings $35.9M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SI-BONE, Inc. reported fiscal year 2023 results: revenue $128 million to $131 million. Guidance raised.

Period: fiscal year 2023
Revenue: $128 million to $131 million
Guidance: raised
Result: guidance update

Exact text from the filing

SI-BONE is updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SI-BONE, Inc. reported the quarter ended March 31, 2023 results: revenue $32.7 million.

Period: the quarter ended March 31, 2023
Revenue: $32.7 million
Result: preliminary results

Exact text from the filing

musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2023. Recent Highlights • Record world wide revenue of $32.7 million for the first quarter 2023, representing approximately 46% increase over the corresponding period in 2022 • Record U.S. revenue of $30.5 million for the first quarter 2023,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-23-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.